MPIA
AZN icon

Mountain Pacific Investment Advisers’s AstraZeneca AZN Stock Holding History

Mountain Pacific Investment Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-317
Closed -$25K – 119
2018
Q3 		$25K Buy
+317
New +$24K ﹤0.01% 215

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mountain Pacific Investment Advisers's AZN Position: Q4 2018 in Review

Mountain Pacific Investment Advisers sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 317 shares — an estimated $25K sold.

Mountain Pacific Investment Advisers first reported a position in AZN in Q3 2018 and held it in 1 quarter. The position peaked at $25K in Q3 2018. 557 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

  • Mountain Pacific Investment Advisers reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
  • Mountain Pacific Investment Advisers sold 317 AstraZeneca shares in Q4 2018, an estimated $25K.
  • Mountain Pacific Investment Advisers first reported a position in AstraZeneca in Q3 2018 and held it in 1 quarter.
  • Mountain Pacific Investment Advisers's AstraZeneca position peaked at $25K in Q3 2018.
  • 557 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on Mountain Pacific Investment Advisers's 13F filing for Q4 2018, filed 25 Jan 2019.